INHIBITION OF THE HIV-1 REV TRANSACTIVATOR
INHIBITION OF THE HIV-1 REV TRANSACTIVATOR
批准号:
3489809
负责人:
Anilkumar Dhundale
金额:
$4.98万
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-08-15 至 1994-02-15
中文摘要
获得性免疫缺陷综合症(艾滋病),一种影响数百万人的疾病,
在全球范围内,患者死亡率很高。的
这种疾病的病原体,传染性逆转录病毒HIV-1,
被证明对治疗干预是难治的。唯一使用的药物
今天的临床目标是病毒逆转录酶。这些药物充其量
暂时延缓疾病进展。此外,这些代理商还表现出
在有效治疗剂量下具有显著毒性。目前,其他
靶向逆转录酶、病毒蛋白酶或病毒蛋白酶的化合物
达特反式激活因子也在临床试验中。但似乎
很明显,可能需要额外的药物来靶向其他步骤,
病毒复制一个这样的靶点是Rev反式激活因子,
对病毒复制至关重要。Rev的功能是诱导核
导出部分拼接和未拼接的病毒信息,
感染性HIV-1的结构基因产物和RNA基因组
粒子我们建议建立一个Rev依赖性的双报告基因测定法,
结合Oncogene Science独特的基于细胞的高通量
筛选技术,能够评估超过123,000
化合物,以确定铅化合物从NCI的自然
产品储存库,它特异性抑制HIV-1 Rev反式-
活化剂。
英文摘要
Acquired Immunodeficiency Syndrome (AIDS), a disease affecting millions of
individuals worldwide, has a high incidence of patient mortality. The
etiological agent of this disease, the infectious retrovirus HIV-l, has
proven refractory to therapeutic intervention. The only drugs used in the
clinic today target the viral reverse transcriptase. At best such drugs
temporarily delay disease progression. In addition, these agents exhibit
significant toxicity at the effective therapeutic dose. Presently, other
compounds, targeting reverse transcriptase, viral protease, or the viral
Tat trans-activator, ale also in clinical trials. However, it appears
clear that additional drugs may be needed which target other steps in
viral replication. One such target is the Rev trans-activator, which is
essential for viral replication. The function of Rev is to induce-nuclear
export of the partially spliced and unspliced viral messages, which encode
the structural gene products and the RNA genome, for infectious HIV-1
particles. We propose to create a Rev-dependent, double reporter assay
combined with Oncogene Science's unique cell based high-throughput
screening technology, which is capable of evaluating over 123,000
compounds per year, to identify lead compounds from the NCI's natural
product repository, which specifically inhibit the HIV-1 Rev trans-
activator.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TRANSLOCATION ASSAY BY PCR AMPLIFICATION IN SITU
-
批准号:3493086
-
项目类别:
-
资助金额:$4.86万
-
财政年份:1992
-
负责人:Anilkumar Dhundale
-
依托单位:
YEAST MRNA 3' END FORMATION AS AN ANTIFUNGAL DRUG TARGET
-
批准号:3489044
-
项目类别:
-
资助金额:$4.94万
-
财政年份:1989
-
负责人:Anilkumar Dhundale
-
依托单位:
海外基金